Recent investigations have converged on the convergence of glucagon-like peptide-1|GIP|GCGR agonist therapies and dopamine neurotransmission. While GLP agonists are commonly employed for managing type 2 diabetes, their unexpected effects on reward circuits, specifically governed by dopaminergic pathways, are receiving significant focus. This rep… Read More